Ewing肉瘤生物学的进展是继续导致重要死亡原因的原因之一，已引起与疾病潜在分子基础相关的文献信息和新治疗方法的讨论增加。本研究旨在全面分析已发表的关于Ewing肉瘤的科学文章。使用Web of Science数据库获取和统计1980年至2021年间发表的关于Ewing肉瘤的文章。使用网络可视化地图揭示趋势主题，全球合作以及最有效的研究。使用Spearman相关系数进行相关性分析。共分析了3236篇文章。贡献最多和最密切合作的前三个国家是美国（1194, 36.8％），德国（293, 9％），意大利（254, 7.8％）。儿科血液与癌症（n = 122），癌症（87），儿科血液及肿瘤学杂志（71）是发表最多文章的三个期刊之一。最活跃的作者是Piero Picci（n = 94）。高收入国家对该主题的文献产生了很大影响。近年来，最研究的趋势主题包括儿科肿瘤学、EWS RNA结合蛋白1（EWSR1）、EWSR1-FL1、表观遗传学、生物信息学、微RNA、基因表达、转移、迁移、生物标志物、免疫治疗、生存率、结果、监测流行病学和最终结果（SEER）、定量计算、奥莫莫德和伊立替康，以及药物耐药性。近年来研究的主题包括基因研究、转移、免疫治疗、基于SEER获得的新数据的生命分析/计量图以及伊立替康和奥莫莫德联合化疗。版权所有© 2022作者。 Wolters Kluwer Health, Inc.发布。

Advances in the biology of Ewing sarcoma, which continues to be an important cause of mortality, have caused an increase in information in the literature related to the underlying molecular base of the disease and discussions of new treatment approaches. In this study, we aimed to comprehensively analyze the published scientific articles on Ewing sarcoma. The Web of Science database was used to obtain and statistically analysis articles on Ewing sarcoma that were published between 1980 and 2021. Maps of network visualization were used to reveal trending topics, global collaborations, and the most effective studies. Correlation analysis was performed using Spearman's correlation coefficient. A total of 3236 articles were analyzed. The first 3 countries that contributed the most to the literature and cooperated most intensively were USA (1194, 36.8%), Germany (293, 9%), Italy (254, 7.8%). Pediatric Blood & Cancer (n = 122), Cancer (87), Journal of Pediatric Hematology Oncology (71) were among the top 3 journals with the most articles. The most active author was Piero Picci (n = 94). High-income countries have a great effect on the literature on this subject. The most studied trend topics in recent years were pediatric oncology, EWS RNA Binding Protein 1 (EWSR1), EWSR1-FL1, epigenetics, bioinformatics, microRNA, gene expression, metastasis, migration, biomarker, immunotherapy, survival, outcomes, surveillance epidemiology and end results (SEER), nomogram, temozolomide, irinotecan, and drug resistance. Genetic studies, metastasis, immunotherapy, life analyses/nomogram based on new data obtained from SEER, and chemotherapy with irinotecan and temozolomide combination, were seen to be the topics researched in recent years.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.